United Therapeutics Corporation
United Therapeutics Announces Positive Ralinepag Results in PAH Clinical Trial
Summary
United Therapeutics Corporation announced positive results from its ADVANCE OUTCOMES clinical study of ralinepag in patients with pulmonary arterial hypertension (PAH). The study met its primary endpoint, showing a 55% reduction in the risk of clinical worsening events with ralinepag compared to placebo. Additionally, ralinepag demonstrated improvements in several secondary endpoints, including a 47% increase in the odds of achieving clinical improvement. The safety profile was consistent with known prostacyclin-related adverse events, and no new safety signals were observed. United Therapeutics plans to submit a New Drug Application (NDA) for ralinepag to the U.S. Food and Drug Administration (FDA) by the second half of 2026.
Profitelligence Alerts
Get alerts for UTHR
Be first to know when United Therapeutics Corporation files with the SEC.
Filing Categories
Advertisement
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company engaged in the development and commercialization of innovative pharmaceutical products. Primarily focusing on therapies to address unmet medical needs for chronic and life-threatening conditions, United Therapeutics is notable for its contributions in the field of pulmonary arterial hypertension (PAH). The company offers a portfolio of products that include both oral and inhaled treatments, such as Remodulin and Tyvaso, providing critical care solutions that significantly improve patients' quality of life. Additionally, they are investing in innovative technologies such as organ manufacturing and regenerative medicine, showcasing a commitment to future medical advances. Headquartered in Silver Spring, Maryland, United Therapeutics operates across various stages of drug research, from clinical trials to post-market analysis. As a key player in the biotechnology industry, the company holds an influential position, contributing to significant advancements in therapeutic solutions and reinforcing its role in the healthcare market by addressing complex medical challenges and patient needs effectively.
Official SEC Documents
Advertisement